Latest news with #HRS
Time of India
11-07-2025
- Health
- Time of India
‘Census-2027 to be a digital exercise'
Lucknow: UP Census Director Sheetal Verma said on Friday the census exercise scheduled for 2027 will be conducted digitally through a mobile app. This will enable data collection and publication with accuracy and transparency in much less time. She said approximately 600,000 field staff will be deployed in Uttar Pradesh for census operations. "This will be the first post-independence census to collect caste-related data as well. The first phase will occur over a 30-day period between April and Sep 2026, and the second phase will run from Feb 9 to Feb 28, 2027," she said, while speaking at a seminar on 'Demography and Civil Registration System'. The reference time for census enumeration will be March 1 at 00:00 HRS. This census will also include a self-enumeration option. She said UP has made qualitative improvements in birth and death registration and is now among the leading states in the country. Mission director (National Programme), Medical & Health Dr Shubhra Mishra said since Feb 1, 2020, birth and death registrations have been processed online via the portal. She said newborn certificates are issued to families at discharge from govt hospitals. Private hospitals have also been provided data entry IDs to submit information directly to the registrar through the CRS portal. These efforts, she said, greatly expedited registrations within 21 days. According to 2022 data, Uttar Pradesh is ahead of states like Karnataka and Kerala in this regard, Mishra said. Registration is now carried out across approximately 62,000 units, including rural, urban, and health department facilities.
Medscape
18-06-2025
- Health
- Medscape
Dementia Rates Show Generational Decrease
Dementia prevalence among older adults was significantly lower among individuals born more recently (1944-1948) compared to those born earlier (1919-1923), with a more pronounced decline in women, a new study conducted in the US, Europe, and England showed. METHODOLOGY: In this cross-sectional study, data were obtained from the US Health and Retirement Study (HRS; 1994-2021; n = 21,069); the Survey of Health, Aging and Retirement in Europe (SHARE; 2004-2020; n = 32,490); and the English Longitudinal Study of Aging (ELSA; 2002-2019; n = 8878). The study focused on individuals aged 71 years or older. Validated algorithm and machine learning methods were used to identify individuals with potential dementia. Participants were divided into six age groups and assigned to 22 birth cohorts: Eight from HRS, seven from SHARE, and seven from ELSA. The earliest birth cohort in each dataset served as the reference cohort, and all analyses were adjusted for age and period effects. TAKEAWAY: Individuals born between 1944 and 1948 had a significantly lower risk for dementia than those born between 1919 and 1923 across all regions (point estimates: US, -0.55 vs -0.18; Europe, -1.49 vs -0.24; England, -0.48 vs -0.23). Women had a more pronounced decrease in dementia risk compared to men in the 1944-1948 birth cohort (point estimates: US, -0.55 vs -0.48; Europe, -1.50 vs -1.34; England, -0.76 vs -0.07). Among individuals aged 81-85 years, dementia prevalence varied notably across birth cohorts, with rates in the US declining from 25% (1890-1913 cohort) to 16% (1939-1943 cohort) and in Europe from 30% (1934-1938 cohort) to 15% (1939-1943 cohort). IN PRACTICE: 'The generational decrease in dementia risk has important implications for healthcare planning, long-term care policies, and workforce requirements in aging populations,' the investigators wrote. SOURCE: This study was led by Xiaoxue Dou, Centre for the Business and Economics of Health, The University of Queensland, Brisbane, Australia. It was published online on June 2 in JAMA Network Open . LIMITATIONS: Study limitations included incomplete data across survey waves, particularly the omission of SHARE wave 3, and by variable inconsistencies that required algorithm adjustments. Dementia prevalence may have been underestimated due to mortality between waves. Sampling bias was possible, especially owing to the underrepresentation of racial and ethnic minorities in ELSA. The retrospective design also prevented the validation of data collection methods. Additionally, the study did not explore the causes underlying the decline in dementia rates. DISCLOSURES: For funding, one investigator reported receiving a PhD scholarship from The University of Queensland. No relevant conflicts of interest were reported.
Yahoo
14-06-2025
- Health
- Yahoo
4 Nutrients You Should Be Eating to Help Lower Dementia Risk, According to a New Study
Reviewed by Dietitian Annie Nguyen, M.A., RDA new study suggests that several nutrients are linked with a lower risk of dementia. These nutrients include vitamins and minerals that act as antioxidants, plus fiber. High sugar intake was related to an increased risk of we age, it's natural to become more forgetful. But when the occasional 'Where did I leave my keys?' becomes forgetting loved ones' names and your own address, it may be a sign of something more serious. Dementia is a general term for loss of memory, language, problem-solving and other thinking abilities, severe enough to interfere with everyday life. Alzheimer's disease is the most common type of dementia. Unfortunately, dementia cases are expected to double by the year 2060. And the economic burden of unpaid dementia caregiving in the U.S. is expected to skyrocket from an average of $172 billion in 2020 to over $1.5 trillion by 2060. And this doesn't take into account the emotional toll on families, friends and caregivers. Since there is currently no cure for dementia, taking preventative measures can be a wise move. Columbia University researchers wanted to know which nutrients were related to a reduced risk of dementia—and which ones might increase the risk. They recently published their findings in Nutrients. Let's break down what they found. Related: 6 Things You Should Do After 5 P.M. to Support Healthy Aging, According to Experts Researchers drew data from the Health and Retirement Study (HRS), an ongoing U.S. study conducted biennially since 1992 that includes adults 50 years and older. In 2013, food consumption and nutrition intake was collected from a subset of the HRS called the Healthcare and Nutrition Study (HCNS). To evaluate diet, participants completed a food frequency questionnaire that asked how frequently they consumed 163 different foods and beverages over the past 12 months. From this, the research team calculated nutrient intake based on participants' responses for 101 nutrients. Individual nutrients were assessed regarding their relationship to dementia. In addition, researchers calculated composite scores for some groups of nutrients. Participants' cognitive abilities were assessed using two different methods. One method was via a telephone interview with participants and the other was via a proxy respondent. For the proxy method, someone close to the participant answered questions about the participant's memory levels, limitations in instrumental activities of daily living and status of cognitive impairment. Researchers would use this information to look for associations between nutrient intake and dementia risk. This current study included 6,280 HCNS participants who met the researchers' criteria, which included full diet information and cognitive assessments. Researchers also adjusted for demographic information like age, race, sex, BMI, education level, smoking status, alcohol intake and physical activity. After running statistical analyses, the results suggest that several nutrients were connected with a reduced risk of dementia. The five with the strongest association were: Isorhamnetin, a type of flavonol Manganese, a mineral Dietary fiber Beta-tocopherol and beta-tocotrienol, both forms of vitamin E This study also adds to the mounting evidence that high sugar intake is linked with a higher risk of dementia. With that said, it also showed some controversial associations between some other nutrients and higher dementia risk. We say controversial because they conflict with previous research or add to mixed results. For example, this study suggests a link between certain components in milk and an increased risk of dementia, including glycerophosphocholine and vitamin D, both of which have been shown to support brain health in other studies. Researchers note that more research needs to be done, and that it could be due to other components in the food, not necessarily these nutrients. This study has several limitations. First, asking people to estimate how much they ate of certain foods over the last year leaves lots of room for bias, forgetfulness and guessing. Also, cognitive abilities and dementia were not clinically evaluated, which also leaves room for bias. Lastly, researchers did not adjust for factors like genetics and environmental factors that play a role in dementia. Related: The #1 Nutrient for Brain Health as You Age, According to a Dietitian Isorhamnetin is a flavonol found in fruits and vegetables, including onions, almonds, berries, cherries, pears, apples and green grapes. It's also found in ginkgo biloba, an herb touted for its brain health benefits. You'll find manganese in nuts, legumes, whole grains and leafy greens. Maple syrup and maple water are also rich sources of this trace mineral. Manganese plays a role in many bodily processes, including metabolism and immunity. While it's a mineral, manganese plays a dual role and acts like an antioxidant, protecting cells from damage from free radicals. Like manganese, vitamin E also has antioxidant properties, protecting cells from damage. Nuts, seeds, wheat germ, and sunflower and safflower oils are good sources of vitamin E. You'll also get some in spinach and broccoli. A whopping nine out of 10 Americans don't have enough fiber in their diets. Fiber-rich foods include fruits, vegetables, nuts, seeds, whole grains and legumes. If you're concerned that you're not including enough of these nutrients in your day-to-day routine, consider shaking things up. An easy (and painless) way to do it is to swap out your typical snacks for nutrient-rich ones. For example, if you typically reach for chips, soda or a candy bar mid-afternoon, consider a handful of nuts and berries. Or how about some hummus and veggie sticks? If you're ready to go all in and want some guidance, check out our MIND diet meal plans. The MIND diet is a fusion of the Mediterranean and DASH diets, and is loaded with brain-healthy foods that are also good for your heart. There is recent evidence that following this healthy eating pattern may reduce your risk of dementia by up to 25%. In addition to food, physical activity, managing your stressors and getting plenty of quality sleep also influence brain health. And make sure you're also spending time with loved ones, as loneliness has also been shown to increase dementia risk. Related: 6 Habits That May Be Aging Your Brain, According to Experts This study suggests that certain nutrients, like vitamin E, manganese and isorhamnetin, all of which act like antioxidants, plus fiber, are linked with a lower risk of dementia. It also adds to existing evidence that high sugar intake may raise dementia risk. If possible, get these brain-protecting nutrients from food. If you have difficulty doing so, seek the advice of a registered dietitian or a healthcare professional who can help you integrate foods rich in these nutrients and determine if supplementation is a viable option for you. Read the original article on EATINGWELL
Yahoo
13-06-2025
- Yahoo
OBX Week on HRS: Stories From The Outer Edge
PORTSMOUTH, Va. (WAVY) – All this week we're spotlighting North Carolina's Outer has partnered with The Outer Banks Visitors Bureau to bring you an in-depth and unique perspective that you may not have seen before. We have a different focus each day thanks to some fantastic videos they've created and are allowing us to share on HRS. The series is called and today's focuses on Mother Nature's Playground. Lee Nettles with The Outer Banks Visitors Bureau shared more about the series. The Outer Banks Visitors Bureau1 Visitors Center Circle, Manteo, North Carolina(252) 473-2138 or visit This segment of The Hampton Roads Show is sponsored by The Outer Banks Visitors Bureau. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Cision Canada
13-05-2025
- Business
- Cision Canada
Thryv Therapeutics to Share Recent Clinical Results and Participate in Upcoming Healthcare Investor Conferences
MONTREAL, May 13, 2025 /CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today announced its participation in two upcoming prominent investor conferences in New York City. The company will share recent clinical results in Long QT Syndrome presented at the 2025 Heart Rhythm Society Annual Meeting and recent developments for its pre-clinical and clinical programs for both heart failure and atrial fibrillation. Clinical Results Presented at HRS 2025 On April 27, 2025, Thryv presented new clinical data from Part 2 of the Wave I study at the Heart Rhythm Society (HRS) Annual Meeting. The study enrolled adult patients with genetically confirmed Long QT Syndrome Type 2 or Type 3 who received oral doses of LQT-1213 at either 7 mg TID or 16 mg TID for 2⅓ days (seven total doses). LQT-1213 appeared to be generally well-tolerated across both dose groups. Clinically meaningful and statistically significant reductions in QTcF interval were observed in the high dose cohort. Key regulatory endpoints for Long QT Syndrome – such as QTcF area under the curve (AUC) and maximal peak-to-trough effects – demonstrated mean reductions of up to 11 milliseconds (p=0.028) for QTcF AUC. In a subsequent analysis of peak-to-trough changes, the 53 milliseconds (p<0.0001) reduction in QTc is consistent with publications of other drugs studied but not approved for this indication. These results provide important clinical proof-of-concept that LQT-1213 – part of Thryv's series of highly selective SGK1 inhibitors – may offer a disease-modifying approach and lay the foundation for continued clinical development of SGK1 Inhibitors for Long QT Syndrome. Upcoming Investor Conferences RBC Capital Markets Global Healthcare Conference 2025 Dates: May 20–21, 2025 Fireside Chat: Wednesday, May 21, 2025, at 9:30 am EST (Track IV – 2 nd Floor) Location: InterContinental New York Barclay, New York, NY Thryv Therapeutics will participate in a fireside chat and host one-on-one meetings with investors about its future program plans and Series B financing throughout the conference. Jefferies Global Healthcare Conference 2025 Dates: June 3–5, 2025 Location: New York Marriott Marquis, New York, NY Thryv Therapeutics will participate in one-on-one investor meetings. To request a meeting at either conference, please contact: [email protected] Study Highlights Wave I is a multi-part, first-in-human proof-of-concept clinical study designed to evaluate the safety, pharmacokinetics (PK), and efficacy of LQT-1213 in patients with both acquired and congenital forms of Long QT Syndrome. Part 1 results were presented at the American College of Cardiology's Annual Scientific Session in March 2024. Read the full poster here. Part 2 is a single-blind, placebo run-in, multiple-dose safety study in participants with cLQTS Type 2 or 3. Results were presented at the Heart Rhythm Society Annual Meeting in April 2025. Read the full abstract here. More about the Wave I study (Parts 1 and 2) can be found at: About Thyrv's SGK1 Inhibitors Thryv Therapeutics is advancing a series of potent and selective SGK1 (serum and glucocorticoid-regulated kinase 1) inhibitors that target the underlying causes of electrical and structural remodelling which leads to cardiac conditions such as Long QT Syndrome, heart failure, and atrial fibrillation. In heart tissue, SGK1 has been shown to adversely affect ion channel function and surface expression. Its activation is implicated in prolongation of the QT interval, contributing to both congenital and acquired forms of LQTS and adverse outcomes in cardiometabolic diseases such as heart failure and atrial fibrillation. Inhibition of SGK1 may address the root cause of electrical dysfunction and offer a disease-modifying therapy by targeting both electrical and structural remodeling of cardiomyocytes. About Long QT Syndrome (LQTS) Long QT Syndrome (LQTS) is a disorder of the heart's electrical system that delays ventricular repolarization, prolonging the QT interval on an ECG. This can lead to torsade de pointes — a potentially fatal arrhythmia — and sudden cardiac death. LQTS can be congenital, caused by mutations in cardiac ion channel genes (commonly LQT1, LQT2, or LQT3), or acquired, resulting from medications or medical conditions. Congenital LQTS is a rare orphan disease, affecting approximately 1 in 2,000 people worldwide. About Thryv Therapeutics Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat Long QT Syndrome, heart failure and atrial fibrillation with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1). For more information, please visit
